Antibody discovery refers to the process of identifying, engineering, and optimizing antibodies for therapeutic, diagnostic, and research applications. It involves advanced platforms such as phage display, hybridoma technology, single B-cell screening, and transgenic animal models to generate highly specific and clinically viable antibody candidates.
In Europe, antibody discovery has become a strategic pillar of the biologics ecosystem. The increasing demand for fully human and humanized antibodies reflects a strong regional focus on minimizing immunogenicity, enhancing safety, and improving target specificity. These antibodies are critical in addressing complex diseases such as oncology, autoimmune disorders, infectious diseases, and rare conditions.
The Europe antibody discovery market is projected to reach $10.13 billion by 2035 from $3.23 billion in 2025, growing at a CAGR of 12.11% during the forecast period 2025-2035. The market is expanding rapidly due to strong biomedical research infrastructure, widespread adoption of automation and artificial intelligence, and continuous innovation in antibody engineering technologies.
Download the complete TOC and Request Sample Report
• Strong and sustained demand for targeted biologics in oncology, autoimmune diseases, and chronic conditions
• Increasing R&D investments by pharmaceutical companies and rising venture capital funding for antibody-focused biotech startups
• Rapid advancements in high-throughput screening, next-generation sequencing, single-cell analysis, and microfluidics
• Growing emphasis on fully human and humanized antibodies to improve clinical safety and efficacy
• Supportive regulatory outlook for biologics and precision medicine across major European markets
• Cost and productivity pressures encouraging outsourcing to specialized contract research organizations (CROs)
• Expansion of academic-industry collaborations strengthening early-stage discovery pipelines
• Limited availability of standardized, high-quality datasets for training and validating AI-driven discovery models
• High capital and operational costs associated with advanced discovery platforms and digital infrastructure
• Intellectual property complexities surrounding AI-designed antibodies and shared datasets
• Regulatory uncertainty regarding validation, reproducibility, and approval pathways for AI-enabled discovery outputs
• Fragmented ecosystem of service providers and technology platforms, complicating vendor benchmarking and selection
• Competition from alternative therapeutic modalities such as gene and cell therapies
• Increasing integration of artificial intelligence and machine learning into antibody discovery workflows for improved target identification and affinity maturation
• Growing adoption of next-generation antibody formats such as bispecific antibodies, antibody-drug conjugates (ADCs), nanobodies, and engineered fragments
• Expansion of integrated, end-to-end discovery platforms combining wet-lab screening with computational biology tools
• Rising outsourcing of discovery and early development activities to European CROs and specialized service providers
• Greater use of function-first and disease-relevant translational assays, including advanced cell-based screening models
According to Principal Analyst at BIS Research: “The Europe antibody discovery market is poised for sustained double-digit growth, supported by strong scientific foundations and rapid digital transformation. The integration of AI, automation, and next-generation sequencing into discovery workflows is significantly shortening timelines and improving candidate quality. As demand for precision biologics continues to rise, Europe’s collaborative ecosystem of academia, biotech firms, CROs, and pharmaceutical companies will play a pivotal role in shaping the future of targeted therapeutics.”
The Europe antibody discovery market is projected to grow from $3.23 billion in 2025 to $10.13 billion by 2035, at a CAGR of 12.11% during the forecast period 2025-2035.
Key factors include AI-driven modeling, automation, high-throughput screening, next-generation sequencing, and advancements in antibody engineering technologies such as phage display and transgenic animal models.
Bispecific antibodies, antibody-drug conjugates (ADCs), nanobodies, and engineered fragments are gaining increasing attention due to their expanded therapeutic potential and improved targeting capabilities.
Contract research organizations play a critical role in enhancing scalability, improving cost-efficiency, and providing access to specialized technical expertise across the antibody discovery value chain.
BIS Research provides expert-driven insights, granular segmentation, and strategic advisory across life sciences, biotechnology, and deep technology domains.
